Company intelligence / Profile preview

Ascidian Therapeutics

Boston, Massachusetts, United Statesascidian-tx.com ↗

Ownership: Private
Employees: ~75
Development stage: Other

Overview

Ascidian has advanced the first-ever RNA exon editor from lab to clinic for Stargardt disease. The company also has discovery and preclinical programs in retinal, neurological, neuromuscular, and genetically defined diseases. A major research collaboration with Roche was launched in 2024 focused on neurology. No detailed clinical results have been published yet as of August 2024.

Therapeutic areas: Rare DiseasesOphthalmologyNeurology
Modalities: RNA exon editing (pre-mRNA trans-splicing)RNA therapeutics
Industry: Biotech

Drug pipeline

2 assets

ACDN-01

1 more asset in the full pipeline.

Partnerships

Roche (neurology research collaboration announced in June/August 2024; up to $1.8B milestones possible)

Beyond the preview

Go deeper on Ascidian Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ascidian Therapeutics.